Citi analyst John Deakin-Bell expects Nexstellis to become a positive contributor to earnings in fiscal 2023, and forecast peak sales of $US100 million the following year - about half of Mayne’s $US200 million target.As a result of FDA approval, Mayne Pharma will pay Mithra $11 million in cash and issue 85.8 million ordinary shares.
Citi analyst John Deakin-Bell expects Nexstellis to become a...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.98 |
Change
-0.040(0.80%) |
Mkt cap ! $405.4M | |||
| Open | High | Low | Value | Volume |
| $5.00 | $5.00 | $4.94 | $102.5K | 20.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 727 | $4.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.99 | 2752 | 6 |
View Market Depth
| Last trade - 11.37am 26/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |